You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Berdazimer sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for berdazimer sodium and what is the scope of freedom to operate?

Berdazimer sodium is the generic ingredient in one branded drug marketed by Lnhc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Berdazimer sodium has fifty-eight patent family members in nine countries.

Summary for berdazimer sodium
International Patents:58
US Patents:14
Tradenames:1
Applicants:1
NDAs:1
Clinical Trials: 2
DailyMed Link:berdazimer sodium at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for berdazimer sodium
Generic Entry Date for berdazimer sodium*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
GEL;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for berdazimer sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Synteract, Inc.Phase 3
Novan, Inc.Phase 3

See all berdazimer sodium clinical trials

US Patents and Regulatory Information for berdazimer sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lnhc ZELSUVMI berdazimer sodium GEL;TOPICAL 217424-001 Jan 5, 2024 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Lnhc ZELSUVMI berdazimer sodium GEL;TOPICAL 217424-001 Jan 5, 2024 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Lnhc ZELSUVMI berdazimer sodium GEL;TOPICAL 217424-001 Jan 5, 2024 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for berdazimer sodium

Country Patent Number Title Estimated Expiration
European Patent Office 3556401 PARTICULES LIBÉRANT DE L'OXYDE NITRIQUE POUR THÉRAPIE À BASE D'OXYDE NITRIQUE ET APPLICATIONS BIOMÉDICALES (NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS) ⤷  Subscribe
Canada 3062005 GELS TOPIQUES (TOPICAL GELS) ⤷  Subscribe
Japan 2019167364 局所用組成物及びこれを使用する方法 (TOPICAL COMPOSITIONS AND METHODS OF USING THE SAME) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.